EA201692495A8 - Биспецифические антитела к il4-il13 - Google Patents

Биспецифические антитела к il4-il13

Info

Publication number
EA201692495A8
EA201692495A8 EA201692495A EA201692495A EA201692495A8 EA 201692495 A8 EA201692495 A8 EA 201692495A8 EA 201692495 A EA201692495 A EA 201692495A EA 201692495 A EA201692495 A EA 201692495A EA 201692495 A8 EA201692495 A8 EA 201692495A8
Authority
EA
Eurasian Patent Office
Prior art keywords
fragments
antibody
double
region
binding proteins
Prior art date
Application number
EA201692495A
Other languages
English (en)
Other versions
EA201692495A1 (ru
Inventor
Коринн Эспере
Александр Ягершмидт
Кристина Субран
Арун Субраманиам
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of EA201692495A1 publication Critical patent/EA201692495A1/ru
Publication of EA201692495A8 publication Critical patent/EA201692495A8/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В данном документе раскрыты безопасные дозы антителоподобных связывающих белков с двойной V-областью или их фрагментов, а также способы оценивания связывания антителоподобных белков с двойной V-областью или их фрагментов со своими мишенями и способы лечения идиопатического легочного фиброза (IPF) путем введения безопасных доз антителоподобных связывающих белков с двойной V-областью или их фрагментов. Согласно некоторым вариантам осуществления антителоподобные связывающие белки с двойной V-областью или их фрагменты связываются как с IL-4, так и с IL-13.
EA201692495A 2014-06-27 2015-06-26 Биспецифические антитела к il4-il13 EA201692495A8 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462018253P 2014-06-27 2014-06-27
EP14306477 2014-09-24
US201562102097P 2015-01-11 2015-01-11
US201562102555P 2015-01-12 2015-01-12
PCT/IB2015/001377 WO2015198146A2 (en) 2014-06-27 2015-06-26 Anti-il4-il 13 bispecific antibodies

Publications (2)

Publication Number Publication Date
EA201692495A1 EA201692495A1 (ru) 2017-05-31
EA201692495A8 true EA201692495A8 (ru) 2017-07-31

Family

ID=51663114

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692495A EA201692495A8 (ru) 2014-06-27 2015-06-26 Биспецифические антитела к il4-il13

Country Status (18)

Country Link
US (2) US20170145089A1 (ru)
EP (1) EP3160502A2 (ru)
JP (1) JP2017530089A (ru)
KR (1) KR102558891B1 (ru)
CN (1) CN106573975A (ru)
AU (1) AU2015278829B2 (ru)
BR (1) BR112016030568B8 (ru)
CA (1) CA2952902C (ru)
CL (1) CL2016003317A1 (ru)
CR (1) CR20170022A (ru)
EA (1) EA201692495A8 (ru)
MX (1) MX2017000171A (ru)
NZ (1) NZ728020A (ru)
PH (1) PH12016502569A1 (ru)
SG (2) SG10201811562YA (ru)
TN (1) TN2016000569A1 (ru)
TW (2) TWI745962B (ru)
WO (1) WO2015198146A2 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
TWI745962B (zh) 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法
WO2020242989A1 (en) 2019-05-24 2020-12-03 Sanofi Methods for treating systemic sclerosis
IL315265A (en) * 2022-03-03 2024-10-01 Pfizer Inc Multiple antibodies and their uses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US20040023338A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
US20040023337A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity
CA2587903A1 (en) 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2008087194A (ja) 2006-09-29 2008-04-17 Brother Ind Ltd インクジェットプリンタ
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8454955B2 (en) * 2007-11-28 2013-06-04 Riken Methods for treating allergic airway inflammation, airway hypersensitivity, and eosinophilia
JP5439915B2 (ja) 2009-04-09 2014-03-12 ユニマテック株式会社 硬化性含フッ素ポリエーテル組成物
MX2011011729A (es) * 2009-05-05 2012-04-10 Novimmune Sa Anticuerpo anti il-17f y metodos de uso de los mismos.
JP5305366B2 (ja) 2009-10-26 2013-10-02 国立大学法人大阪大学 画像特徴抽出装置、画像特徴抽出方法、画像認識装置、及び画像認識方法
EP2496944A2 (en) * 2009-11-05 2012-09-12 Novartis AG Biomarkers predictive of progression of fibrosis
CA2817380C (en) 2010-12-16 2019-06-04 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
CN110624107A (zh) * 2012-08-21 2019-12-31 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗或预防哮喘的方法
RS57520B1 (sr) * 2012-09-07 2018-10-31 Regeneron Pharma Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
TW201542226A (zh) 2014-02-12 2015-11-16 Sanofi Sa 抗－ｉｌ－４／抗－ｉｌ－１３雙特異性抗體／聚麩胺酸配製物
TWI745962B (zh) 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法

Also Published As

Publication number Publication date
TWI745962B (zh) 2021-11-11
CL2016003317A1 (es) 2017-08-11
EA201692495A1 (ru) 2017-05-31
CN106573975A (zh) 2017-04-19
BR112016030568B1 (pt) 2023-10-17
NZ728020A (en) 2022-07-01
TW201628647A (zh) 2016-08-16
CA2952902C (en) 2024-02-13
BR112016030568A2 (pt) 2018-02-20
JP2017530089A (ja) 2017-10-12
AU2015278829A1 (en) 2017-02-02
BR112016030568B8 (pt) 2023-12-05
CR20170022A (es) 2017-04-04
KR20170020519A (ko) 2017-02-22
WO2015198146A2 (en) 2015-12-30
AU2015278829B2 (en) 2021-03-25
KR102558891B1 (ko) 2023-07-21
TW202034954A (zh) 2020-10-01
US20190359703A1 (en) 2019-11-28
SG10201811562YA (en) 2019-01-30
PH12016502569A1 (en) 2017-04-17
US11136388B2 (en) 2021-10-05
WO2015198146A3 (en) 2016-03-31
TN2016000569A1 (en) 2018-04-04
CA2952902A1 (en) 2015-12-30
MX2017000171A (es) 2017-04-25
SG11201610594WA (en) 2017-01-27
EP3160502A2 (en) 2017-05-03
US20170145089A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
EA201891093A1 (ru) Антитела, специфически связывающие pd-1, и их применение
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
PE20170665A1 (es) Anticuerpos anti-tau humanizados
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA201492101A1 (ru) Антитела против fcrn
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201492149A1 (ru) St2-антигенсвязывающие белки
EA201892774A1 (ru) Антитела
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EA201591791A1 (ru) Антитела pac1 человека
EA201790438A1 (ru) Антигенсвязывающие белки, которые связываются с cxcr5
EA201690503A1 (ru) Антитела
EA201992206A1 (ru) Моноклональное антитело к pd-l1